Skip to content

AcuCort strengthens its organization and appoints interim CEO

AcuCort AB (Spotlight Stock Market: ACUC) today announces that the company strengthens its organization and hires Ann Gidner as interim CEO. The current CEO Mats Lindfors will continue to work for AcuCort in a consulting role. The change will take effect on January 1, 2020.

The current CEO Mats Lindfors has to the board expressed his wishes to scale down his involvement in AcuCort due to family reasons. The now announced change means that Ann Gidner takes over as interim CEO of AcuCort on January 1, 2020. At the same time, Mats Lindfors takes up a consulting role as support during a transitional period and as responsible for certain projects in AcuCort’s business plan. The recruitment of a permanent CEO of AcuCort is in progress.

Ann Gidner has solid experience from senior positions in the pharmaceutical industry and life science. Her many years of experience includes roles as Head of the CTS Business Unit at Inceptua GmbH in Berlin, Licensing Director at Albumedix A/S (Novozymes Biopharma) and as CEO of the pharma strategy company Monocl AB. She has previous extensive experience of global commercial responsibility in large international CMO corporations. Ann has built the business model and created strong sales growth at Cambrex Corporation with placement in Sweden and New Jersey, USA, and at Saltigo GmbH with placement in Germany. She is also a board member of SenzaGen AB since 2014.

Ann Gidner holds a master’s degree in biotechnology from Lund University, Faculty of Engineering (LTH) and the French Ecole Nationale Supérieure d’Ingénieurs de Génie Chimique (ENSIGC) and an MBA from Lund University.

“I am immensely pleased that AcuCort has managed to bring in Ann Gidner, who has solid competence and international experience in areas that are vital to the company. In addition, we have found a solution enabling AcuCort’s current CEO Mats Lindfors to continue to work actively as a consultant, which secures continuity and a good transition and adds resources,” says Ebba Fåhraeus, Chairman of the board in AcuCort AB.

“AcuCort is an exciting company and ISICORT® is an innovative product candidate with great potential. I have worked with various aspects of drug development and commercialization throughout my working life and look forward to leading the work towards the approval and commercialization, of primarily ISICORT®,” says AcuCort’s incoming interim CEO Ann Gidner.

“I find today’s announcement positive for AcuCort as well as for myself personally. I have for some time wanted to change my work situation. My new role as consultant means that I can continue working for AcuCort, but to a more limited extent, at the same time as new skills and new perspectives are added to the company. All in all, I think this is an excellent solution,” says AcuCort’s current CEO Mats Lindfors.

For further information, please contact
Ebba Fåhraeus, Chairman of the board, AcuCort AB                                                                                              Phone: +46 73 400 04 33

About AcuCort
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe was carried out with positive results and a national hybrid application has been submitted to the Swedish Medical Products Agency. Taken together, this strengthens the company’s assessment that the time until commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Learn more at